Psychological and somatic symptoms among breast cancer patients in four European countries: A cross-lagged panel model

BOUNCE consortium

doi:10.1002/smi.3193

Psychological and somatic symptoms among breast cancer patients in four European countries: A cross-lagged panel model

BOUNCE consortium

The Paul Baerwald School of Social Work and Social Welfare

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Psychological and physical health among women with breast cancer are linked. However, more research is needed to test the interrelations between psychological and somatic symptoms, over time and throughout the different phases of breast cancer treatment, to determine when and which interventions should be prioritized. Six hundred and eighty nine women from four countries (Finland, Israel, Italy and Portugal) completed questionnaires during their first clinical consultation following diagnosis with breast cancer, and again after 3 and 6 months. The questionnaires included self-reported measures of psychological symptoms (Hospital Anxiety and Depression Scale; the Positive and Negative Affect Schedule Short Form) and somatic symptoms [selected items from the International European Organization for Research and Treatment of Cancer (EORTC) questionnaires]. Psychological and somatic symptoms were relatively stable across the three time-points. Cross-lagged paths leading from somatic to psychological symptoms (beta coefficients of 0.08–0.10), as well as vice-versa (beta 0.11–0.12), were found to be significant. No evidence was found for cross-cultural differences in mutual effects of psychological and somatic symptoms. The findings of this study call for tailoring personal interventions for breast cancer patients—either from a somatic perspective or a psychological perspective—and adjust them to the specific experiences of the individual patient.

Original language	American English
Pages (from-to)	474-482
Number of pages	9
Journal	Stress and Health
Volume	39
Issue number	2
DOIs	https://doi.org/10.1002/smi.3193
State	Published - Apr 2023

Bibliographical note

Funding Information:
Albino J. Oliveira‐Maia was national coordinator for Portugal of a non‐interventional study (EDMS‐ERI‐143085581, 4.0) to characterize a Treatment‐Resistant Depression Cohort in Europe, sponsored by Janssen‐Cilag, Ltd (2019–2020), is recipient of a grant from Schuhfried GmBH for norming and validation of cognitive tests, and is national coordinator for Portugal of trials of psilocybin therapy for treatment‐resistant depression, sponsored by Compass Pathways, Ltd (EudraCT number 2017‐003288‐36 and 2020‐001348‐25), and of Esketamine for treatment‐resistant depression, sponsored by Janssen‐Cilag, Ltd (EudraCT NUMBER: 2019‐002992‐33). The remaining authors have no potential conflicts of interest to declare.

Funding Information:
This project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 777167. Dr Kelada is supported by the Golda Meir Post‐Doctoral Fellowship Fund.

Publisher Copyright:
© 2022 The Authors. Stress and Health published by John Wiley & Sons Ltd.

Keywords

breast cancer
psychological symptoms
somatic symptoms
theory of unpleasant symptoms

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/smi.3193

Cite this

@article{159246db632a43eb9d94cbf0d59e7f8c,

title = "Psychological and somatic symptoms among breast cancer patients in four European countries: A cross-lagged panel model",

abstract = "Psychological and physical health among women with breast cancer are linked. However, more research is needed to test the interrelations between psychological and somatic symptoms, over time and throughout the different phases of breast cancer treatment, to determine when and which interventions should be prioritized. Six hundred and eighty nine women from four countries (Finland, Israel, Italy and Portugal) completed questionnaires during their first clinical consultation following diagnosis with breast cancer, and again after 3 and 6 months. The questionnaires included self-reported measures of psychological symptoms (Hospital Anxiety and Depression Scale; the Positive and Negative Affect Schedule Short Form) and somatic symptoms [selected items from the International European Organization for Research and Treatment of Cancer (EORTC) questionnaires]. Psychological and somatic symptoms were relatively stable across the three time-points. Cross-lagged paths leading from somatic to psychological symptoms (beta coefficients of 0.08–0.10), as well as vice-versa (beta 0.11–0.12), were found to be significant. No evidence was found for cross-cultural differences in mutual effects of psychological and somatic symptoms. The findings of this study call for tailoring personal interventions for breast cancer patients—either from a somatic perspective or a psychological perspective—and adjust them to the specific experiences of the individual patient.",

keywords = "breast cancer, psychological symptoms, somatic symptoms, theory of unpleasant symptoms",

author = "{BOUNCE consortium} and Ilan Roziner and Shlomit Perry and Rawan Dahabre and Gabriella Bentley and Lauren Kelada and Paula Poikonen-Saksela and Ketti Mazzocco and Berta Sousa and Karademas, {Evangelos C.} and Panagiotis Simos and Gretta Pettini and Oliveira-Maia, {Albino J.} and Johanna Mattson and Ruth Pat-Horenczyk",

note = "Funding Information: Albino J. Oliveira‐Maia was national coordinator for Portugal of a non‐interventional study (EDMS‐ERI‐143085581, 4.0) to characterize a Treatment‐Resistant Depression Cohort in Europe, sponsored by Janssen‐Cilag, Ltd (2019–2020), is recipient of a grant from Schuhfried GmBH for norming and validation of cognitive tests, and is national coordinator for Portugal of trials of psilocybin therapy for treatment‐resistant depression, sponsored by Compass Pathways, Ltd (EudraCT number 2017‐003288‐36 and 2020‐001348‐25), and of Esketamine for treatment‐resistant depression, sponsored by Janssen‐Cilag, Ltd (EudraCT NUMBER: 2019‐002992‐33). The remaining authors have no potential conflicts of interest to declare. Funding Information: This project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 777167. Dr Kelada is supported by the Golda Meir Post‐Doctoral Fellowship Fund. Publisher Copyright: {\textcopyright} 2022 The Authors. Stress and Health published by John Wiley & Sons Ltd.",

year = "2023",

month = apr,

doi = "10.1002/smi.3193",

language = "American English",

volume = "39",

pages = "474--482",

journal = "Stress and Health",

issn = "1532-3005",

publisher = "John Wiley and Sons Inc.",

number = "2",

}

TY - JOUR

T1 - Psychological and somatic symptoms among breast cancer patients in four European countries

T2 - A cross-lagged panel model

AU - BOUNCE consortium

AU - Roziner, Ilan

AU - Perry, Shlomit

AU - Dahabre, Rawan

AU - Bentley, Gabriella

AU - Kelada, Lauren

AU - Poikonen-Saksela, Paula

AU - Mazzocco, Ketti

AU - Sousa, Berta

AU - Karademas, Evangelos C.

AU - Simos, Panagiotis

AU - Pettini, Gretta

AU - Oliveira-Maia, Albino J.

AU - Mattson, Johanna

AU - Pat-Horenczyk, Ruth

N1 - Funding Information: Albino J. Oliveira‐Maia was national coordinator for Portugal of a non‐interventional study (EDMS‐ERI‐143085581, 4.0) to characterize a Treatment‐Resistant Depression Cohort in Europe, sponsored by Janssen‐Cilag, Ltd (2019–2020), is recipient of a grant from Schuhfried GmBH for norming and validation of cognitive tests, and is national coordinator for Portugal of trials of psilocybin therapy for treatment‐resistant depression, sponsored by Compass Pathways, Ltd (EudraCT number 2017‐003288‐36 and 2020‐001348‐25), and of Esketamine for treatment‐resistant depression, sponsored by Janssen‐Cilag, Ltd (EudraCT NUMBER: 2019‐002992‐33). The remaining authors have no potential conflicts of interest to declare. Funding Information: This project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 777167. Dr Kelada is supported by the Golda Meir Post‐Doctoral Fellowship Fund. Publisher Copyright: © 2022 The Authors. Stress and Health published by John Wiley & Sons Ltd.

PY - 2023/4

Y1 - 2023/4

N2 - Psychological and physical health among women with breast cancer are linked. However, more research is needed to test the interrelations between psychological and somatic symptoms, over time and throughout the different phases of breast cancer treatment, to determine when and which interventions should be prioritized. Six hundred and eighty nine women from four countries (Finland, Israel, Italy and Portugal) completed questionnaires during their first clinical consultation following diagnosis with breast cancer, and again after 3 and 6 months. The questionnaires included self-reported measures of psychological symptoms (Hospital Anxiety and Depression Scale; the Positive and Negative Affect Schedule Short Form) and somatic symptoms [selected items from the International European Organization for Research and Treatment of Cancer (EORTC) questionnaires]. Psychological and somatic symptoms were relatively stable across the three time-points. Cross-lagged paths leading from somatic to psychological symptoms (beta coefficients of 0.08–0.10), as well as vice-versa (beta 0.11–0.12), were found to be significant. No evidence was found for cross-cultural differences in mutual effects of psychological and somatic symptoms. The findings of this study call for tailoring personal interventions for breast cancer patients—either from a somatic perspective or a psychological perspective—and adjust them to the specific experiences of the individual patient.

AB - Psychological and physical health among women with breast cancer are linked. However, more research is needed to test the interrelations between psychological and somatic symptoms, over time and throughout the different phases of breast cancer treatment, to determine when and which interventions should be prioritized. Six hundred and eighty nine women from four countries (Finland, Israel, Italy and Portugal) completed questionnaires during their first clinical consultation following diagnosis with breast cancer, and again after 3 and 6 months. The questionnaires included self-reported measures of psychological symptoms (Hospital Anxiety and Depression Scale; the Positive and Negative Affect Schedule Short Form) and somatic symptoms [selected items from the International European Organization for Research and Treatment of Cancer (EORTC) questionnaires]. Psychological and somatic symptoms were relatively stable across the three time-points. Cross-lagged paths leading from somatic to psychological symptoms (beta coefficients of 0.08–0.10), as well as vice-versa (beta 0.11–0.12), were found to be significant. No evidence was found for cross-cultural differences in mutual effects of psychological and somatic symptoms. The findings of this study call for tailoring personal interventions for breast cancer patients—either from a somatic perspective or a psychological perspective—and adjust them to the specific experiences of the individual patient.

KW - breast cancer

KW - psychological symptoms

KW - somatic symptoms

KW - theory of unpleasant symptoms

UR - http://www.scopus.com/inward/record.url?scp=85137505582&partnerID=8YFLogxK

U2 - 10.1002/smi.3193

DO - 10.1002/smi.3193

M3 - Article

C2 - 35997497

AN - SCOPUS:85137505582

SN - 1532-3005

VL - 39

SP - 474

EP - 482

JO - Stress and Health

JF - Stress and Health

IS - 2

ER -

Psychological and somatic symptoms among breast cancer patients in four European countries: A cross-lagged panel model

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this